FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1844107241> ?p ?o ?g. }

• W1844107241 endingPage "5257" @default.
• W1844107241 startingPage "5240" @default.
• W1844107241 abstract "// Sue Ellen Verbrugge 1,11 , Marjon Al 1 , Yehuda G. Assaraf 2 , Sarah Kammerer 1,3,12 , Durga M.S.H. Chandrupatla 1,3 , Richard Honeywell 3 , Rene P.J. Musters 4 , Elisa Giovannetti 3 , Tom O’Toole 5 , George L. Scheffer 6 , David Krige 7,13 , Tanja D. de Gruijl 3 , Hans W.M. Niessen 6 , Willem F. Lems 1 , Pieternella A. Kramer 8 , Rik J. Scheper 6 , Jacqueline Cloos 9 , Gert J. Ossenkoppele 10 , Godefridus J. Peters 3 and Gerrit Jansen 1 1 Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands 2 The Fred Wyszkowsky Cancer Research Laboratory, Faculty of Biology, The Technion-Israel Institute of Technology, Haifa, Israel 3 Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands 4 Department of Physiology, VU University, Amsterdam, The Netherlands 5 Department of Molecular Cell Biology, VU University, Amsterdam, The Netherlands 6 Departments of Pathology and Cardiac Surgery, ICaR-VU, VU University Medical Center, Amsterdam, The Netherlands 7 Chroma Therapeutics Ltd, Abingdon, United Kingdom 8 Isala Hospital, Zwolle, The Netherlands 9 Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands 10 Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands 11 Present address: Department of Clinical Chemistry, UMCU, Utrecht, The Netherlands 12 Present address: Institute of Biophysics, Medical University of Graz, Graz, Austria 13 Present address: Immunocore Ltd, Oxford, UK  Correspondence to: Gerrit Jansen, email: // Keywords : aminopeptidase, carboxylesterase, lipid droplets, mTOR, rapamycin Received : August 11, 2015 Accepted : October 04, 2015 Published : October 19, 2015 Abstract Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally available hydrophobic aminopeptidase inhibitor prodrug with an esterase-sensitive motif, in myeloid leukemia cells. CHR2863 enters cells by diffusion and is retained therein upon esterase activity-mediated conversion to its hydrophilic active metabolite drug CHR6768, thereby exerting amino acid depletion. Carboxylesterases (CES) serve as candidate prodrug activating enzymes given CES1 expression in acute myeloid leukemia specimens. We established two novel myeloid leukemia sublines U937/CHR2863(200) and U937/CHR2863(5uM), with low (14-fold) and high level (270-fold) CHR2863 resistance. The latter drug resistant cells displayed: (i) complete loss of CES1-mediated drug activation associated with down-regulation of CES1 mRNA and protein, (ii) marked retention/sequestration of the prodrug, (iii) a substantial increase in intracellular lipid droplets, and (iv) a dominant activation of the pro-survival Akt/mTOR pathway. Remarkably, the latter feature coincided with a gain of sensitivity to the mTOR inhibitor rapamycin. These finding delineate the molecular basis of CHR2863 resistance and offer a novel modality to overcome this drug resistance in myeloid leukemia cells." @default.
• W1844107241 created "2016-06-24" @default.
• W1844107241 creator A5007946879 @default.
• W1844107241 creator A5013852274 @default.
• W1844107241 creator A5017991794 @default.
• W1844107241 creator A5018592613 @default.
• W1844107241 creator A5020883449 @default.
• W1844107241 creator A5031445293 @default.
• W1844107241 creator A5035296183 @default.
• W1844107241 creator A5041229832 @default.
• W1844107241 creator A5042938924 @default.
• W1844107241 creator A5047201420 @default.
• W1844107241 creator A5049292621 @default.
• W1844107241 creator A5049992488 @default.
• W1844107241 creator A5051015262 @default.
• W1844107241 creator A5053105927 @default.
• W1844107241 creator A5063387835 @default.
• W1844107241 creator A5065784242 @default.
• W1844107241 creator A5070729528 @default.
• W1844107241 creator A5075695885 @default.
• W1844107241 creator A5084411642 @default.
• W1844107241 creator A5085426388 @default.
• W1844107241 date "2015-10-19" @default.
• W1844107241 modified "2023-09-26" @default.
• W1844107241 title "Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR" @default.
• W1844107241 cites W1495123612 @default.
• W1844107241 cites W1523693806 @default.
• W1844107241 cites W1553539229 @default.
• W1844107241 cites W1583557220 @default.
• W1844107241 cites W1691930647 @default.
• W1844107241 cites W1805898977 @default.
• W1844107241 cites W1849728743 @default.
• W1844107241 cites W1862079335 @default.
• W1844107241 cites W1871566045 @default.
• W1844107241 cites W1940068179 @default.
• W1844107241 cites W1969989200 @default.
• W1844107241 cites W1973432561 @default.
• W1844107241 cites W1973470114 @default.
• W1844107241 cites W1974730258 @default.
• W1844107241 cites W1975229775 @default.
• W1844107241 cites W1975286848 @default.
• W1844107241 cites W1983342808 @default.
• W1844107241 cites W1990854324 @default.
• W1844107241 cites W1998445948 @default.
• W1844107241 cites W2004341894 @default.
• W1844107241 cites W2010163650 @default.
• W1844107241 cites W2015746068 @default.
• W1844107241 cites W2019943090 @default.
• W1844107241 cites W2020780403 @default.
• W1844107241 cites W2022335352 @default.
• W1844107241 cites W2026215813 @default.
• W1844107241 cites W2027976496 @default.
• W1844107241 cites W2029094565 @default.
• W1844107241 cites W2032261812 @default.
• W1844107241 cites W2036299072 @default.
• W1844107241 cites W2038371153 @default.
• W1844107241 cites W2038867755 @default.
• W1844107241 cites W2044191806 @default.
• W1844107241 cites W2048214220 @default.
• W1844107241 cites W2049517768 @default.
• W1844107241 cites W2049843699 @default.
• W1844107241 cites W2059941395 @default.
• W1844107241 cites W2060024988 @default.
• W1844107241 cites W2062646606 @default.
• W1844107241 cites W2071149267 @default.
• W1844107241 cites W2073900832 @default.
• W1844107241 cites W2084162137 @default.
• W1844107241 cites W2087728192 @default.
• W1844107241 cites W2089492300 @default.
• W1844107241 cites W2092628520 @default.
• W1844107241 cites W2094517081 @default.
• W1844107241 cites W2100510340 @default.
• W1844107241 cites W2102561304 @default.
• W1844107241 cites W2103818458 @default.
• W1844107241 cites W2105961905 @default.
• W1844107241 cites W2115603990 @default.
• W1844107241 cites W2122245179 @default.
• W1844107241 cites W2123383613 @default.
• W1844107241 cites W2127063807 @default.
• W1844107241 cites W2128442187 @default.
• W1844107241 cites W2128832687 @default.
• W1844107241 cites W2131536053 @default.
• W1844107241 cites W2134806571 @default.
• W1844107241 cites W2139192127 @default.
• W1844107241 cites W2140737563 @default.
• W1844107241 cites W2140802932 @default.
• W1844107241 cites W2141729412 @default.
• W1844107241 cites W2151049164 @default.
• W1844107241 cites W2151639840 @default.
• W1844107241 cites W2152420092 @default.
• W1844107241 cites W2153497031 @default.
• W1844107241 cites W2153607816 @default.
• W1844107241 cites W2155069742 @default.
• W1844107241 cites W2155711100 @default.
• W1844107241 cites W2156936195 @default.
• W1844107241 cites W2162327900 @default.
• W1844107241 cites W2162657734 @default.
• W1844107241 cites W2171490806 @default.

• next